Interpretation of urine drug testing in pain patients

Pain Medicine (United States)

Volumn 13, Issue 7, 2012, Pages 868-885

  Pesce, Amadeo ^a   West, Cameron ^a   Egan City, Kathy ^a   Strickland, Jennifer ^a  

^a Millennium Research Institute   (United States)

Author keywords

Alcohol Use; Drug Metabolism; Pain Medication; Patient Compliance; Urine Drug Testing

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; COCAINE; CODEINE; DEXTROPROPOXYPHENE; DRUG METABOLITE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; METHAMPHETAMINE; MORPHINE; OXYCODONE; OXYMORPHONE; PETHIDINE; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; DRUG ABUSE; DRUG DETERMINATION; DRUG FORMULATION; DRUG IMPURITY; DRUG METABOLISM; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; PAIN; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REVIEW; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE DRUG TEST;

EID: 84863883705     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01350.x     Document Type: Review

References (179)

1. House of Delagates of the Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. 2004. Available at: (accessed May 25, 2010).
2. Chou R, Fanciullo GJ, Fine PG, etal. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):131-46.
3. Trescot AM, Boswell MV, Atluri SL, etal. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9(1):1-40.
4. Trescot AM, Helm S, Hansen H, etal. Opioids in the management of chronic non-cancer pain: An update of American Society of Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician 2008;11(2):S5-62.
5. Trescot AM, Glaser SE, Hansen H, etal. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008;11(2):S181-200.
6. McNicol E, Horowicz-Mehler N, Fisk RA, etal. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 2003;4(5):231-56.
7. Simons SHP, Anand KJS. Pain control: Opioid dosing, population kinetics and side-effects. Semin Fetal Neonatal Med 2006;11(4):260-7.
8. Benyamin R, Trescot AM, Datta S, etal. Opioid complications and side effects. Pain Physician 2008;11(2):S105-20.
9. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11(2):S133-53.
10. Manchikanti L, Manchikanti KN, Pampati V, Cash KA. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain. Pain Physician 2009;12(1):259-67.
11. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications, and management options. Pain Med 2009;10(4):654-62.
12. PDR Network. Physician's Desk Reference, 65th edition. Montvale, NJ: PDR Network, LLC; 2011.
13. Bohnert AS, Valenstein M, Bair MJ, etal. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305(13):1315-21.
14. Geller AS. Opioid overdose-related deaths. JAMA 2011;306(4):379-81.
15. Centers for Disease Control and Prevention. Prescription painkiller overdoses in the US. Retrieved from (accessed March 27, 2012).
16. Paulozzi LJ, Kilbourne EM, Shah NG, etal. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012;13(1):87-95.
17. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: Prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm 2008;14(6):553-60.
18. Fischer MA, Stedman MR, Lii J, etal. Primary medication non-adherence: Analysis of 195, 930 electronic prescriptions. J Gen Intern Med 2010;25(4):284-90.
19. Goldman L, Epstein AM. Improving adherence-Money isn't the only thing. N Engl J Med 2011;365(22):2131-3.
20. Choudhry NK, Avorn J, Glynn RJ, etal. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365(22):2088-97.
21. Berndt S, Maier C, Schiitz H. Polymedication and medication compliance in patients with chronic non-malignant pain. Pain 1993;52(3):331-9.
22. Gourlay D, Heit HA. The art and science of urine drug testing. Clin J Pain 2010;26(4):358.
23. Adams NJ, Plane MB, Fleming MF, etal. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001;22(3):791-6.
24. Ballantyne JC. Opioid misuse in oncology pain patients. Curr Pain Headache Rep 2007;11(4):276-82.
25. Becker WC, Meghani SH, Barth KS, Wiedemer N, Gallagher RM. Characteristics and outcomes of patients discharged from the Opioid Renewal Clinic at the Philadelphia VA Medical Center. Am J Addict 2009;18(2):135-9.
26. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: Is there a problem? Eur J Pain 2009;13(2):115-23.
27. Couto JE, Webster L, Romney MC, Leider HL, Linden A. Using an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen. J Clin Pharm Ther 2011;36(2):200-7.
28. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9(4):444-59.
29. Fishman SM, Wilsey B, Yang J, etal. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 2000;20(4):293-307.
30. Fleming M, Balousek S, Klessig C, Mundt M, Brown D. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8(7):573-82.
31. Gatti A, Mammucari M, Sabato E, Masucci L, Sabato AF. Adherence and long-term effect of oxycodone/paracetamol in chronic noncancer pain: A retrospective study. Adv Ther 2011;28(5):418-26.
32. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107-12.
33. Graziottin A, Gardner-Nix J, Stumpf M, Berliner MN. Opioids: How to improve compliance and adherence. Pain Pract 2011;11(6):574-81.
34. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids: Study of chronic pain patients. Can Fam Physician 2006;52(9):1081-7.
35. Kirsh KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain 2002;18(4):S52-60.
36. Krebs EE, Ramsey DC, Miloshoff JM, Bair MJ. Primary care monitoring of long-term opioid therapy among veterans with chronic pain. Pain Med 2011;12(5):740-6.
37. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care 2011;17(1):32-40.
38. Meghani SH, Wiedemer NL, Becker WC, Gracely EJ, Gallagher RM. Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med 2009;10(5):858-65.
39. Michna E, Ross EL, Hynes WL, etal. Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage 2004;28(3):250-8.
40. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry 2008;30(2):93-9.
41. Morasco BJ, Duckart JP, Dobscha SK. Adherence to clinical guidelines for opioid therapy for chronic pain in patients with substance use disorder. J Gen Intern Med 2011;26(9):965-71.
42. Passik SD, Kirsh KL, Donaghy K, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22(2):173-81.
43. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med 2007;8(7):573-84.
44. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: What we know and what we need to further know. Med Care 2005;43(6):517-20.
45. Manchikanti L, Damron K, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study. Pain Physician 2004;7(4):431-7.
46. Manchikanti L, Manchukonda R. Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician 2005;8(3):257-61.
47. Couto JE, Romney MC, Leider HL, Sharma S, Goldfarb NI. High rates of inappropriate drug use in the chronic pain population. Popul Health Manag 2009;12(4):185-90.
48. Sherman MF, Bigelow GE. Validity of patients' self-reported drug use as a function of treatment status. Drug Alcohol Depend 1992;30(1):1-11.
49. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999;15(3):184-91.
50. Jung B, Reidenberg MM. Physicians being deceived. Pain Med 2007;8(5):433-7.
51. Webster LR, Dove B. Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners. North Branch, MN: Sunrise River Press; 2007.
52. Tennant F. Opioid blood levels. Pract Pain Manag 2011;11(1):7.
53. Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. California Academy of Family Physicians. Stamford, CT: PharmaCom Group, Inc.; 2010.
54. Allen KR, Azad R, Field HP, Blake DK. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann Clin Biochem 2005;42(Pt 4):277-84.
55. Kintz P, Villain M, Concheiro M, Cirimele V. Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int 2005;150(2-3):213-20.
56. Toennes SW, Steinmeyer S, Maurer HJ, Moeller MR, Kauert GF. Screening for drugs of abuse in oral fluid-Correlation of analysis results with serum in forensic cases. J Anal Toxicol 2005;29(1):22-7.
57. Wood M, Laloup M, Fernandez M, etal. Quantitative analysis of multiple illicit drugs in preserved oral fluid by solid-phase extraction and liquid chromatography-tandem mass spectrometry. Forensic Sci Int 2005;150(2-3):227-38.
58. Wylie F, Torrance H, Anderson R, Oliver J. Drugs in oral fluid Part I. Validation of an analytical procedure for licit and illicit drugs in oral fluid. Forensic Sci Int 2005;150(2-3):191-8.
59. Drummer OH. Drug testing in oral fluid. Clin Biochem Rev 2006;27(3):147-59.
60. Heltsley R, Depriest A, Black DL, etal. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol 2011;35(8):529-40.
61. Vindenes V, Yttredal B, Oiestad EL, etal. Oral fluid is a viable alternative for monitoring drug abuse: Detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with methadone or buprenorphine. J Anal Toxicol 2011;35(1):32-9.
62. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol 2008;32(8):530-43.
63. Pesce A, West C, Egan-City K, Clarke W. Diagnostic accuracy and interpretation of urine drug testing for pain patients: An evidence-based approach. In: Acree B, ed. Toxicity and Drug Testing. Rijeka, Croatia: InTech-Open Access Publisher; 2011:25-64.
64. Manchikanti L, Manchukonda R, Pampati V, etal. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006;9(2):123-9.
65. Pesce A, West C, Rosenthal M, etal. Illicit drug use in the pain patient population decreases with more frequent drug testing. Pain Physician 2011;14(2):189-93.
66. Bhamb B, Brown D, Hariharan J, etal. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22(9):1859-65.
67. Toombs JD. Commonsense opioid-risk management in chronic noncancer pain: A clinician's perspective. Pain Treatment Topics: Pain Treatment Topics, 2007. Available at: (accessed November 22, 2011).
68. Reisfield GM, Webb FJ, Bertholf RL, Sloan PA, Wilson GR. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag 2007;3(6):333-7.
69. Reisfield GM, Bertholf RL. "Practical guide" to urine drug screening clarified. Mayo Clin Proc 2008;83(7):848-9.
70. West R, Pesce A, Mikel C, etal. Observations of medication compliance by measurement of urinary drug concentrations in a pain management population. J Opioid Manag 2010;6(4):253-7.
71. Levy S, Sherritt L, Vaughan BL, Germak M, Knight JR. Results of random drug testing in an adolescent substance abuse program. Pediatrics 2007;119(4):e843-8.
72. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007;37(4):301-14.
73. Passik SD, Kirsh KL. Screening for opioid abuse potential. Pain Clin Update 2008;16(7):1-4.
74. Webster L, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6(6):432-42.
75. Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med 2007;22(4):485-90.
76. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors Are predictive of current substance use and mental Health problems in primary care patients. Pain Med 2008;9(8):1098-106.
77. Gallagher RM, Rosenthal LJ. Chronic pain and opiates: Balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 2008;89(3):S77-82.
78. Morgan LA, Weaver MF. Preventing prescription opioid overdose. J Clin Outcomes Manag 2010;17(1):511-8.
79. Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11(7):602-11.
80. Kirsh KL, Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. Pain Med 2011;12(suppl 1):S1-11.
81. Starrels JL, Becker WC, Weiner MG, etal. Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med 2011;26(9):958-64.
82. Tellioglu T. The use of urine drug testing to monitor patients receiving chronic opioid therapy for persistent pain conditions. Med Health R I 2008;91(9):279-80, 82.
83. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8(2):171-83.
84. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008;11(2):S63-88.
85. Meatherall R. Optimal enzymatic hydrolysis of urinary benzodiazepine conjugates. J Anal Toxicol 1994;18(7):382-4.
86. Fraser AD, Meatherall R. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: Effect of lowering the screening and GC-MS cut-off values. J Anal Toxicol 1996;20(4):217-23.
87. Meatherall R, Fraser AD. Comparison of four immunoassays for the detection of lorazepam in urine. Ther Drug Monit 1998;20(6):673-5.
88. Wu AH, McKay C, Broussard LA, etal. National academy of clinical biochemistry laboratory medicine practice guidelines: Recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem 2003;49(3):357-79.
89. Shurman J, Backer RC. Focus on urine drug monitoring. Pract Pain Manag 2006;6(2):60-7.
90. Vincent EC, Zebelman A and Goodwin C. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract 2006;55(10):893-7.
91. Glover SJ, Allen KR. Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: Confirmation of samples screened by immunoassay. Ann Clin Biochem 2009;47(2):111-7.
92. Manchikanti L, Malla Y, Wargo BW, etal. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: A prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician 2010;13(1):E1-22.
93. Pesce A, Rosenthal M, West R, etal. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010;13(3):273-81.
94. Manchikanti L, Malla Y, Wargo BW, Fellows B. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. Pain Physician 2011;14(2):175-87.
95. Manchikanti L, Malla Y, Wargo BW, Fellows B. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing. Pain Physician 2011;14(3):259-70.
96. Dams R, Murphy CM, Lambert WE, Huestis MA. Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2003;17(14):1665-70.
97. Dahn T, Gunn J, Kriger S, Terrell AR. Quantitation of morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6-monoacetylmorphine (6-MAM) in urine, blood, serum, or plasma using liquid chromatography with tandem mass spectrometry detection. In: Garg U, Hammler-Stabler C, eds. Clinical Applications of Mass Spectrometry, Methods in Molecular Biology. New York: Humana Press; 2010:411-22.
98. Depriest A, Heltsley R, Black DL, etal. Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use. J Anal Toxicol 2010;24(8):444-9.
99. Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol 2000;24(7):530-5.
100. U.S. Food and Drug Administration. Propoxyphene: Withdrawal-Risk of Cardiac Toxicity. MedWatch: FDA U.S. Food and Drug Administration, 2010. Available at: (accessed February 21, 2011).
101. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Nucynta-Tapentadol. 2010. Available at: (accessed December 3, 2010). Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.
102. Endo Pharmaceuticals. Opana (oxymorphone hydrochloride) package insert. Chadds Ford, PA: Endo Pharmaceuticals; 2006.
103. Eckhardt K, Li S, Ammon S, etal. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998;76(1-2):27-33.
104. Flockhart DA. Drug interactions: Cytochrome P450 drug interaction table. Indiana University School of Medicine, 2007. Available at: (accessed October 12, 2011).
105. Reisfield GM, Goldberger BA, Bertholf RL. "False-positive" and "false-negative" test results in clinical urine drug testing. Bioanalysis 2009;1(5):937-52.
106. Evans M, Kriger S, Gunn J, Schwilke G. Effective monitoring of opiates in chronic pain patients. Pract Pain Manag 2009;9(6):32-3.
107. Haddox JD, Kupper RJ, Cone EJ. Clinical considerations for interpretation of unexpected results from urine drug testing. Presented at The 27th Annual Meeting of the American Academy of Pain Medicine in Washington, DC, 2011.
108. West R, Crews B, Mikel C, etal. Anomalous observations of codeine in patients on morphine. Ther Drug Monit 2009;31(6):776-8.
109. West R, West C, Crews B, etal. Anomalous observations of hydrocodone in patients on oxycodone. Clin Chim Acta 2011;412(1-2):29-32.
110. Heltsley R, Zichterman A, Black DL, etal. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. J Anal Toxicol 2010;34(1):32-8.
111. Cone EJ, Zichterman A, Heltsley R, etal. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic Sci Int 2010;198(1-3):58-61.
112. Valentine JL, Middleton R, Sparks C. Identification of urinary benzodiazepines and their metabolites: Comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens. J Anal Toxicol 1996;20(6):416-24.
113. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010;200(1-3):141-7.
114. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: Mode of action, identification and legislation. Toxicol Lett 2010;197(3):157-62.
115. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("Q-ball"). Am J Psychiatry 2007;164(1):173-4.
116. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. ED visits involving the muscle relaxant carisoprodol. In: The DAWN Report. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, October 2011.
117. Hattab EM, Goldberger BA, Johannsen LM, etal. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: Use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci 2000;31(1):85-91.
118. Wingert WE. Lowering cutoffs for initial and confirmation testing for cocaine and marijuana: Large-scale study of effects on the rates of drug-positive results. Clin Chem 1997;43(1):100-3.
119. Fraser AD. Psychotropic Agents: The Benzodiazepines. In: Shaw LC, Kwong TC, Rosano TG, etal., eds. The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Washington, DC: American Association for Clinical Chemistry, Inc.; 2001:211-21.
120. Kurisaki E, Hayashida M, Nihira M, etal. Diagnostic performance of Triage for benzodiazepines: Urine analysis of the dose of therapeutic cases. J Anal Toxicol 2005;29(6):539-43.
121. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003;25(6):723-27.
122. Beck O, Lafolie P, Hjemdahl P, etal. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: Two techniques evaluated and modified for improved performance. Clin Chem 1992;38(2):271-5.
123. Beck O, Lin Z, Brodin K, Borg S, Hjemdahl P. The online screening technique for urinary benzodiazepines: Comparison with EMIT, FPIA, and GC-MS. J Anal Toxicol 1997;21(7):554-7.
124. Fitzgerald R. Analytical toxicology of the benzodiazepines. Ther Drug Monit Toxicol 1995;16:169-86.
125. West R, Pesce A, West C, etal. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 2010;13(1):71-8.
126. Pesce A, West C, West R, etal. Determination of medication cutoff values in a pain patient population. J Opioid Manag 2011;7(2):117-22.
127. West R, Pesce A, Crews B, etal. Determination of illicit drug cutoff values in a pain patient population. Clin Chim Acta 2011;412(17-18):1589-93.
128. Drayer DE. Pharmacologically active drug metabolites: Therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet 1976;1(6):426-43.
129. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41(14):1153-93.
130. Danielson TJ, Mozayani A and Sanchez LA. Methadone and methadone metabolites in postmortem specimens. Forensic Sci Med Pathol 2008;4(3):170-4.
131. Wasan AD, Michna E, Janfaza D, etal. Interpreting urine drug tests: Prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med 2008;9(7):918-23.
132. Nieminen TH, Hagelberg NM, Saari TI, etal. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009;110(6):1371-8.
133. Larson MEM, Richards TM. Quantification of a methadone metabolite (EDDP) in urine: Assessment of compliance. Clin Med Res 2009;7(4):134-41.
134. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of theCYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010;54(2):232-40.
135. Buchard A, Linnet K, Johansen SS, etal. Postmortem blood concentrations of r- and s-enantiomers of methadone and EDDP in drug users: Influence of co-medication and p-glycoprotein genotype. J Forensic Sci 2010;55(2):457-63.
136. Kell MJ. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis 1994;13(1):5-26.
137. Kell M. United States of America. Patent 5, 547, 878. August 20, 1996.
138. Nafziger AN, Bertino JS Jr. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain 2009;25(1):73-9.
139. Couto JE, Webster L, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. J Opioid Manag 2009;5(6):359-64.
140. Pesce A, West C, West R, etal. Reference intervals: A novel approach to detect drug abuse in a pain patient population. J Opioid Manag 2010;6(5):341-50.
141. National Institute on Alcohol Abuse and Alcoholism. Harmful interactions: Mixing alcohol with medicines. Available at: (accessed February 28, 2012).
142. Jones AW. Urine as a biological specimen for forensic analysis of alcohol and variability in the urine-to-blood relationship. Toxicol Rev 2006;25(1):15-35.
143. Jones AW. Lack of association between urinary creatinine and ethanol concentrations and urine/blood ratio of ethanol in two successive voids from drinking drivers. J Anal Toxicol 1998;22(3):184-90.
144. Helander A, Beck O, Jones AW. Laboratory testing for recent alcohol consumption: Comparison of ethanol, methanol, and 5-hydroxytryptophol. Clin Chem 1996;42(4):618-24.
145. Schmitt G, Droenner P, Skopp G, Aderjan R. Ethyl glucuronide concentration in serum of human volunteers, teetotalers, and suspected drinking drivers. J Forensic Sci 1997;42(6):1099-102.
146. Dahl H, Stephanson N, Beck O, Helander A. Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol 2002;26(4):201-4.
147. Glanz J, Grant B, Monteiro M, Tabakoff B. WHO/ISBRA study on state and trait markers of alcohol Use and Dependence: Analysis of demographic, behavioral, physiologic, and drinking variables that contribute to dependence and seeking treatment. International Society on Biomedical Research on Alcoholism. Alcohol Clin Exp Res 2002;26(7):1047-61.
148. Goll M, Schmitt G, Ganssmann B, Aderjan RE. Excretion profiles of ethyl glucuronide in human urine after internal dilution. J Anal Toxicol 2002;26(5):262-6.
149. Stephanson N, Dahl H, Helander A, Beck O. Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit 2002;24(5):645-51.
150. Bergstrom J. Ethyl glucuronide concentrations in two successive urinary voids from drinking drivers: Relationship to creatinine content and blood and urine ethanol concentrations. Forensic Sci Int 2003;133(1-2):86-94.
151. Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide-The direct ethanol metabolite on the threshold from science to routine use. Addiction 2003;98(2):S51-61.
152. Wurst FM, Wiesbeck GA, Metzger JW, Weinmann W, Graf M. On sensitivity, specificity, and the influence of various parameters on ethyl glucuronide levels in urine-Results from the WHO/ISBRA study. Alcohol Clin Exp Res 2004;28(8):1220-8.
153. Helander A, Beck O. Ethyl sulfate: A metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J Anal Toxicol 2005;29(5):270-4.
154. Wurst FM, Dresen S, Allen JP, etal. Ethyl sulphate: A direct ethanol metabolite reflecting recent alcohol consumption. Addiction 2006;101(2):204-11.
155. Substance Abuse and Mental Health Services Administration. The role of biomarkers in the treatment of alcohol use disorders. Subst Abuse Treat Advis 2006;5(4):1-8.
156. Høiseth G, Bernard JP, Karinen R, etal. A pharmacokinetic study of ethyl glucuronide in blood and urine: Applications to forensic toxicology. Forensic Sci Int 2007;172(2-3):119-24.
157. Niemelä O. Biomarkers in alcoholism. Clin Chim Acta 2007;377(1-2):39-49.
158. Høiseth G, Bernard JP, Stephanson N, etal. Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. Alcohol Alcohol 2008;43(2):187-91.
159. Helander A, Böttcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 2009;44(1):55-61.
160. Wang P. Alcohol. In: Hickman PE, Koerbin G, eds. Methods in Clinical Chemistry Volume I An Accessory Work to the 5th Edition of Kaplan and Pesce's: Clinical Chemistry: Theory, Analysis, Correlation. Maryland Heights, MO: Mosby; 2009:66-79.
161. ThermoFisher Scientific. ThermoFisher Scientific DRI(R) ethyl glucuronide assay. Fremont, CA: ThermoFisher Scientific. 2011.
162. Zimmer H, Schmitt G, Aderjan R. Preliminary immunochemical test for the determination of ethyl glucuronide in serum and urine: Comparison of screening method results with gas chromatography-mass spectrometry. J Anal Toxicol 2002;26(1):11-6.
163. Wojcik MH, Hawthorne JS. Sensitivity of commercial ethyl glucuronide (ETG) testing in screening for alcohol abstinence. Alcohol Alcohol 2007;42(4):317-20.
164. Bottcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol 2007;43(1):46-8.
165. Arndt T, Gierten B, Güssregen B. Werle A, Grüner J. False-positive ethyl glucuronide immunoassay screening associated with chloral hydrate medication as confirmed by LC-MS/MS and self-medication. Forensic Sci Int 2008;184(1-3):e27-9.
166. Crews B, Latyshev S, Mikel C, etal. Improved detection of ethyl glucuronide and ethyl sulfate in a pain management population using high-throughput LC-MS/MS. J Opioid Manag 2010;6(6):415-21.
167. Rosano TG, Lin J. Ethyl glucuronide excretion in humans following oral administration of and dermal exposure to ethanol. J Anal Toxicol 2008;32(8):594-600.
168. Haverstick DM, Bruns DE. Unexpected ethanol in urine: Increasing proof. Clin Chem 2009;56(1):146-7.
169. Helander A, Dahl H. Urinary tract infection: A risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. Clin Chem 2005;51(9):1728-30.
170. Helander A. Olsson I, Dahl H. Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. Clin Chem 2007;53(10):1855-57.
171. Costantino A, Digregorio EJ, Korn W, Spayd S, Rieders F. The effect of the use of mouthwash on ethylglucuronide concentrations in urine. J Anal Toxicol 2006;30(9):659-62.
172. Reisfield GM, Goldberger BA, Crews BO, etal. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. J Anal Toxicol 2011;35(2):85-91.
173. Reisfield GM, Goldberger BA, Pesce AJ, etal. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. J Anal Toxicol 2011;35(5):264-8.
174. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage 2004;27(3):260-7.
175. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.
176. Chou R. 2009 Clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain. Pol Arch Med Wewn 2009;119(7-8):469-77.
177. Portenoy RK. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996;11(4):203-17.
178. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain 2002;18(4):S28-38.
179. Laffer A, Murphy R, Wingarden W, etal. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Available at: (accessed March 27, 2012).